{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:12:04Z","timestamp":1783944724962,"version":"3.55.0"},"reference-count":37,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The clinical course of psoriasis is characterised by marked heterogeneity. Despite the availability of standardised assessment instruments, long-term outcomes at the individual level\u2014encompassing the durability of treatment response, the risk of relapse and the development of comorbidities\u2014remain difficult to predict. To address this uncertainty, numerous prognostic prediction models have been developed; however, their methodological quality, predictive performance and clinical applicability have not yet been systematically appraised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>A systematic search will be conducted across six databases\u2014China National Knowledge Infrastructure, Wanfang Data, VIP Chinese Journal Database, PubMed, Cochrane Library and Embase\u2014from inception to 31 December 2025, using a search strategy combining controlled vocabulary and free-text terms related to psoriasis, prognostic prediction models and relevant outcome measures. Two reviewers will independently perform study selection, data extraction using the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies checklist and risk-of-bias assessment using the Prediction model Risk Of Bias ASsessment Tool. Model performance metrics, including discrimination (eg, the C-statistic) and calibration, will be systematically extracted. Where feasible, random-effects meta-analysis will be performed to pool discrimination estimates across included models. Prespecified subgroup analyses and meta-regression will be employed to investigate potential sources of heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval is not required because this study will analyse publicly available de-identified data from published studies. The results will be submitted to a peer-reviewed journal and presented at relevant conferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117401","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:40:20Z","timestamp":1783942820000},"page":"e117401","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["What is the methodological quality and predictive performance of prognostic prediction models for long-term outcomes in psoriasis? A protocol for a systematic review and meta-analysis"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8802-1512","authenticated-orcid":false,"given":"Juan","family":"Mao","sequence":"first","affiliation":[{"name":"People\u2019s Hospital of HuiLi City, Huili, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7092-1362","authenticated-orcid":false,"given":"Zhaoxin","family":"Yang","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Cai","sequence":"additional","affiliation":[{"name":"Chengdu First People\u2019s Hospital, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shen","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilin","family":"Cheng","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingsheng","family":"Hao","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1524-6452","authenticated-orcid":false,"given":"Zhipeng","family":"Hu","sequence":"additional","affiliation":[{"name":"Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"2026071304401012000_16.7.e117401.1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"2026071304401012000_16.7.e117401.2","doi-asserted-by":"crossref","DOI":"10.1007\/s00403-024-02846-z","article-title":"Global burden and future trends in psoriasis epidemiology: insights from the global burden of disease study 2019 and predictions to 2030","volume":"316","author":"Wang","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2026071304401012000_16.7.e117401.3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19169"},{"key":"2026071304401012000_16.7.e117401.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"2026071304401012000_16.7.e117401.5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2017.05.019","article-title":"Psoriasis and suicidality: A systematic review and meta-analysis","volume":"77","author":"Singh","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026071304401012000_16.7.e117401.6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/ijd.14032","article-title":"Stress and psoriasis","volume":"57","author":"Rousset","year":"2018","journal-title":"Int J Dermatol"},{"key":"2026071304401012000_16.7.e117401.7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084457","article-title":"Psoriasis and Systemic Inflammatory Disorders","volume":"23","author":"Tashiro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026071304401012000_16.7.e117401.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"2026071304401012000_16.7.e117401.9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: Implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026071304401012000_16.7.e117401.10","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.94"},{"key":"2026071304401012000_16.7.e117401.11","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J Dermatol"},{"key":"2026071304401012000_16.7.e117401.12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"2026071304401012000_16.7.e117401.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735"},{"key":"2026071304401012000_16.7.e117401.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.05.016"},{"key":"2026071304401012000_16.7.e117401.15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamadermatol.2014.3593","article-title":"Economic Burden of Psoriasis in the United States: A Systematic Review","volume":"151","author":"Brezinski","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2026071304401012000_16.7.e117401.16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jaad.2015.02.1099","article-title":"Evaluating the economic burden of psoriasis in the United States","volume":"72","author":"Vanderpuye-Orgle","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2026071304401012000_16.7.e117401.17","doi-asserted-by":"crossref","unstructured":"Mao X , Meng S , Wu P , et al . Predictors of clinical response to biologics in psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2026. doi:10.1111\/jdv.70462","DOI":"10.1111\/jdv.70462"},{"key":"2026071304401012000_16.7.e117401.18","first-page":"122","article-title":"S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoring","volume":"24","author":"Nast","year":"2026","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026071304401012000_16.7.e117401.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-18790-9","article-title":"Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)","volume":"12","author":"Graier","year":"2022","journal-title":"Sci Rep"},{"key":"2026071304401012000_16.7.e117401.20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26188998","article-title":"The Association Between Genetics and Response to Treatment with Biologics in Patients with Psoriasis","volume":"26","author":"Loft","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026071304401012000_16.7.e117401.21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/bjd.17625","article-title":"Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review","volume":"181","author":"Mason","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026071304401012000_16.7.e117401.22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaad.2023.06.058","article-title":"Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry","volume":"89","author":"Jin","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2026071304401012000_16.7.e117401.23","first-page":"396","article-title":"Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis","volume":"22","author":"Foster","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2026071304401012000_16.7.e117401.24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/1346-8138.17249","article-title":"Impact of residual skin lesions and previous biologic treatment failure on patient-reported outcomes in patients with psoriasis receiving biologic treatment","volume":"51","author":"Song","year":"2024","journal-title":"J Dermatol"},{"key":"2026071304401012000_16.7.e117401.25","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14186421","article-title":"Early Risk Prediction for Biologic Therapy in Psoriasis Using Machine Learning Models Based on Routine Health Records","volume":"14","author":"Lax","year":"2025","journal-title":"J Clin Med"},{"key":"2026071304401012000_16.7.e117401.26","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.391"},{"key":"2026071304401012000_16.7.e117401.27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.17219\/acem\/69804","article-title":"The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment","volume":"26","author":"Bo\u017cek","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"2026071304401012000_16.7.e117401.28","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/jdv.14960","article-title":"Intra- and interobserver variability of image-based PASI assessments in 120 patients suffering from plaque-type psoriasis","volume":"32","author":"Fink","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026071304401012000_16.7.e117401.29","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026071304401012000_16.7.e117401.30","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2480743","article-title":"Personalized prediction of psoriasis relapse post-biologic discontinuation: a machine learning-driven population cohort study","volume":"36","author":"Huang","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"2026071304401012000_16.7.e117401.31","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026071304401012000_16.7.e117401.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026071304401012000_16.7.e117401.33","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews","volume":"10","author":"Rethlefsen","year":"2021","journal-title":"Syst Rev"},{"key":"2026071304401012000_16.7.e117401.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-073538","article-title":"Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA)","volume":"381","author":"Snell","year":"2023","journal-title":"BMJ"},{"key":"2026071304401012000_16.7.e117401.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"2026071304401012000_16.7.e117401.36","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1376"},{"key":"2026071304401012000_16.7.e117401.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:40:24Z","timestamp":1783942824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,13]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2026-117401"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117401","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}